US PATENT SUBCLASS 435 / 328
.~.~ Immunoglobulin or antibody is chimeric, mutated, or a recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobuin fusion protein, etc.)


Current as of: June, 1999
Click HD for Main Headings
Click for All Classes

Internet Version by PATENTEC © 1999      Terms of Use



435 /   HD   CHEMISTRY: MOLECULAR BIOLOGY AND MICROBIOLOGY

325  DF  ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE {17}
326  DF  .~ Animal cell, per se, expressing immunoglobulin, antibody, or fragment thereof {7}
328.~.~ Immunoglobulin or antibody is chimeric, mutated, or a recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobuin fusion protein, etc.)


DEFINITION

Classification: 435/328

Immunoglobulin or antibody is chimeric, mutated, or a recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.):

(under subclass 326) Subject matter involving an animal cell which produces an antibody or antibody fragment altered with respect to its amino acid sequence; with respect to its composition of heavy and light chains or immunoglobulin domains; or with respect to its glycosylation, as compared with that found in nature; or involving an antibody or antibody fragment fused to a nonimmunoglobulin amino acid sequence.

(1) Note. Chimeric and recombined hybrid antibodies comprise amino acid sequences derived from two or more nonidentical immunoglobulin molecules; e.g., interspecies combinations, etc.

(2) Note. It is suggested that the patents in this subclass be cross-referenced to Class 530, in the appropriate subclasses, 387.1 through 389.8, that provide for the binding specificity of the antibodies employed herein, if disclosed.